Register now!

Patients all over the world should benefit from the achievements of predictive medicine and the introduction of in silico clinical trials (ISCTs), which promise the accelerated and safe introduction of new products such as medical devices or pharmaceuticals to the market place. These concepts cannot be developed by academics or in industry alone, and ultimately they need to be accepted by regulatory agencies around the world. When regulators accept simulation augmented submissions, and agree upon a common model credibility assessment philosophy will patients benefit from the utilization of in silico medicine. 

The objective of the Avicenna Alliance International Working Group is the promotion of the benefits of predictive medicine and ISCTs through the global connections of experts from academia, industry, and regulatory agencies. Together we will work on developing objective standards, increasing confidence in in silico methods and their acceptance in support of regulatory approval process.

Avicenna Alliance news

Boston Scientific joins Avicenna Alliance

As further evidence of the Alliance’s growing momentum, Avicenna Alliance is happy to announce the newest addition to its list of members: Boston...

find out more ›

Meetings at US Senate Buildings

In the week of 15-18 May 2017 the Avicenna Alliance was in Washington DC, following an invitation by the FDA and by the staff of Senator T. Cochran to discuss the...

find out more ›

BMES conference – Frontiers in Medical Devices

In the week of 15-18 May 2017 the Avicenna Alliance was in Washington DC, following an invitation by the FDA and by the staff of Senator T. Cochran to...

find out more ›

Show all activites